Table 1.
Alofisel®/darvadstrocel (n = 27) | Placebo (n = 15) | |
---|---|---|
Age (years) | 35 | 42 |
Male | 12 (44%) | 6 (40%) |
Female | 15 (56%) | 9 (60%) |
Perianal Crohn’s Disease Activity Index Score | 6.1 | 8.6 |
C-reactive protein (nmol/L) | 8.6 | 11.8 |
Treatments | ||
Anti-TNF | 10 (37%) | 8 (54%) |
Immunomodulators | 6 (22%) | 3 (20%) |
anti-TNF and immunomodulators | 5 (19%) | 2 (13%) |
Neither | 6 (22%) | 2 (13%) |